Updates Designation News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Updates Designation. Real-time updates on events, politics, business and more.

National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Pre

March 15, 2022

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous15.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNational Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology...

United States Joe Horvat Practice Research Clinical Haematology Xencor Inc Drug Administration Distribution Services

Source: pharmiweb.com

MorphoSys : National Comprehensive Cancer Network® Updates Designation of Monjuvi® (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas - Form 6-K

March 15, 2022

National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022

United States Thomas Biegi Julia Neugebauer Myles Clouston Jeanette Bressi Joe Horvat

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Updates Designation News Today

National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Pre

MorphoSys : National Comprehensive Cancer Network&#xAE; Updates Designation of Monjuvi&#xAE; (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas - Form 6-K

Explore More Categories

MorphoSys : National Comprehensive Cancer Network® Updates Designation of Monjuvi® (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas - Form 6-K